These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19351857)

  • 21. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
    Chiang EY; Stroynowski I
    J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
    Patel D; Balderes P; Lahiji A; Melchior M; Ng S; Bassi R; Wu Y; Griffith H; Jimenez X; Ludwig DL; Hicklin DJ; Kang X
    Hum Antibodies; 2007; 16(3-4):127-36. PubMed ID: 18334748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
    Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
    J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
    Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
    Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.
    Brandmaier AG; Leitner WW; Ha SP; Sidney J; Restifo NP; Touloukian CE
    J Immunother; 2009 Sep; 32(7):677-88. PubMed ID: 19561540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.
    Singh V; Ji Q; Feigenbaum L; Leighty RM; Hurwitz AA
    J Immunother; 2009; 32(2):129-39. PubMed ID: 19238011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
    Yu Z; Theoret MR; Touloukian CE; Surman DR; Garman SC; Feigenbaum L; Baxter TK; Baker BM; Restifo NP
    J Clin Invest; 2004 Aug; 114(4):551-9. PubMed ID: 15314692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    Overwijk WW; Theoret MR; Finkelstein SE; Surman DR; de Jong LA; Vyth-Dreese FA; Dellemijn TA; Antony PA; Spiess PJ; Palmer DC; Heimann DM; Klebanoff CA; Yu Z; Hwang LN; Feigenbaum L; Kruisbeek AM; Rosenberg SA; Restifo NP
    J Exp Med; 2003 Aug; 198(4):569-80. PubMed ID: 12925674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen localization controls T cell-mediated tumor immunity.
    Zeelenberg IS; van Maren WW; Boissonnas A; Van Hout-Kuijer MA; Den Brok MH; Wagenaars JA; van der Schaaf A; Jansen EJ; Amigorena S; Théry C; Figdor CG; Adema GJ
    J Immunol; 2011 Aug; 187(3):1281-8. PubMed ID: 21705625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.